Session » (0115–0144) Antiphospholipid Syndrome Poster

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0129

Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population

10:30AM-12:30PM: Abstract Number: 0117

Are Thrombotic or Obstetric Events Associated with Additional Clinical Domains in Triple Antiphospholypid Syndrome?

10:30AM-12:30PM: Abstract Number: 0136

Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study

10:30AM-12:30PM: Abstract Number: 0116

Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI

10:30AM-12:30PM: Abstract Number: 0141

Cytokine profiles in antiphospholipid syndrome

10:30AM-12:30PM: Abstract Number: 0128

Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research

10:30AM-12:30PM: Abstract Number: 0133

Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project

10:30AM-12:30PM: Abstract Number: 0144

Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey

10:30AM-12:30PM: Abstract Number: 0115

Dysfunctional Mitophagy Propels Neutrophil Hyperactivity and Thrombosis in Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0138

Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis

10:30AM-12:30PM: Abstract Number: 0143

High-dimensional Spectral Flow Cytometry Reveals a Unique Distribution of Circulating B Cells in Patients with Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0132

Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0137

Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients

10:30AM-12:30PM: Abstract Number: 0131

Libman-Sacks Endocarditis in APS: A Case-Control Study of Clinical and Serologic Features

10:30AM-12:30PM: Abstract Number: 0134

Neutrophil Gasdermin D Pores as Potential Therapeutic Targets in APS-Associated Thromboinflammation

10:30AM-12:30PM: Abstract Number: 0140

Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study

10:30AM-12:30PM: Abstract Number: 0126

Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study

10:30AM-12:30PM: Abstract Number: 0130

Plasminogen activator inhibitor 1 increases thrombotic risk in Antiphospholipid syndrome

10:30AM-12:30PM: Abstract Number: 0123

Prognosis of Cardiac Involvement in Antiphospholipid Syndrome

10:30AM-12:30PM: Abstract Number: 0142

Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis

10:30AM-12:30PM: Abstract Number: 0135

Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes

10:30AM-12:30PM: Abstract Number: 0124

Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome

10:30AM-12:30PM: Abstract Number: 0127

Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease

10:30AM-12:30PM: Abstract Number: 0118

Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome

10:30AM-12:30PM: Abstract Number: 0125

The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 0120

The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

10:30AM-12:30PM: Abstract Number: 0121

The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry

10:30AM-12:30PM: Abstract Number: 0122

The role of low profile antiphospholipid antibodies and adverse pregnancy outcomes.

10:30AM-12:30PM: Abstract Number: 0119

Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0139

When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].